Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of MEDI0382 in overweight and obese adults with type 2 diabetes mellitus
2017-000626-35Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in type 2 diabetes mellitus (T2DM), obesity and Overweight (5 arms), sponsored by AstraZeneca. Primary endpoints: Change in HbA1c from baseline and Percent change in body weight from baseline. Started Jun 2017; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on 2017-000626-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000626-35.